This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
lncRNA LUCAT1 acts as a potential biomarker and demonstrates malignant biological behaviors in gastric cancerlncRNA LUCAT1 acts as a potential biomarker and demonstrates malignant biological behaviors in gastric cancer
Chao Xing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8269-7141
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Gastric cancer(GC) remains the fourth-leading malignancy worldwide and has a high mortality rate.Accumulating evidence reveals that long noncoding RNAs (lncRNAs) play essential roles in tumorigenesis and metastasis and can be used as potential biomarkers for diagnosis and prognosis. The current study sought to define the lncRNA LUCAT1 and verify its malignant biological behaviors in GC. We conducted bioinformatic analysis to screen differentially expressed lncRNAs between GC tissue and paracancerous tissue. Gene expression profiles were downloaded from the National Center of Biotechnology Information Gene Expression Omnibus(GEO). Real-time quantitative polymerase chain reaction (RT-qPCR) was carried out to verify LUCAT1 expression in both GC tissue and paracancerous tissue. Furthermore, the associations between LUCAT1 and clinical features were analyzed. In addition, the malignant behaviors of LUCAT1 in GC were investigated by knocking down LUCAT1 expression in the SGC7901 and AGS cell lines. The results indicated that LUCAT1 expression was obviously upregulated in GC samples compared with paracancerous tissue samples. Moreover, the expression pattern of LUCAT1 showed close correlations with tumor diameter (P<0.001), differentiation grade (P=0.026), and lymphnode metastasis(LNM)status (P=0. 020). In vitro, shRNA-mediated knockdown of LUCAT1 expression inhibited proliferation, migration, and invasion and led to S-phase cell cycle arrest and apoptosisin GC cells. Thus, the lncRNA LUCAT1 may be used as a potential biomarker for early signs of LNM in GC and may play a crucial role in the development of GC.
Keywords
gastric cancer;lncRNA;LUCAT1;biomarker;metastasis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 29 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
lncRNA LUCAT1 acts as a potential biomarker and demonstrates malignant biological behaviors in gastric cancerlncRNA LUCAT1 acts as a potential biomarker and demonstrates malignant biological behaviors in gastric cancer
Chao Xing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8269-7141
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 29 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Gastric cancer(GC) remains the fourth-leading malignancy worldwide and has a high mortality rate.Accumulating evidence reveals that long noncoding RNAs (lncRNAs) play essential roles in tumorigenesis and metastasis and can be used as potential biomarkers for diagnosis and prognosis. The current study sought to define the lncRNA LUCAT1 and verify its malignant biological behaviors in GC. We conducted bioinformatic analysis to screen differentially expressed lncRNAs between GC tissue and paracancerous tissue. Gene expression profiles were downloaded from the National Center of Biotechnology Information Gene Expression Omnibus(GEO). Real-time quantitative polymerase chain reaction (RT-qPCR) was carried out to verify LUCAT1 expression in both GC tissue and paracancerous tissue. Furthermore, the associations between LUCAT1 and clinical features were analyzed. In addition, the malignant behaviors of LUCAT1 in GC were investigated by knocking down LUCAT1 expression in the SGC7901 and AGS cell lines. The results indicated that LUCAT1 expression was obviously upregulated in GC samples compared with paracancerous tissue samples. Moreover, the expression pattern of LUCAT1 showed close correlations with tumor diameter (P<0.001), differentiation grade (P=0.026), and lymphnode metastasis(LNM)status (P=0. 020). In vitro, shRNA-mediated knockdown of LUCAT1 expression inhibited proliferation, migration, and invasion and led to S-phase cell cycle arrest and apoptosisin GC cells. Thus, the lncRNA LUCAT1 may be used as a potential biomarker for early signs of LNM in GC and may play a crucial role in the development of GC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5